ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1216

“I Call It Zombie Hands and Feet, That’s Actually How I Found out I Had This Disease”: Disease Symptoms and Treatment Side Effects in a Diverse Sample of Patients with Early Limited Cutaneous and Diffuse Cutaneous Systemic Sclerosis
Abstract Number: 1094

“Lupus Doesn’t Have Me, I Have Lupus” a Patient Centered Quality Improvement Project to Increase Medication Adherence for Patients with Lupus Nephritis
Abstract Number: 1032

“Not of Your Ethnicity”: A Qualitative Study Exploring Diverse Patient Experiences in Axial Spondyloarthritis (axSpA)
Abstract Number: 1262

“Somebody Who’s Been There and Can Understand the Challenges That You’re Going Through”: Participant Perspectives of a Resilience-Based Energy Management Online Intervention for Systemic Sclerosis with Peer Health Coaches
Abstract Number: 1258

“What Is My Risk Really?”: A Qualitative Exploration and Ideal-Type Analysis of Preventive Interventions Among Individuals at Risk of Rheumatoid Arthritis
Abstract Number: 1691

16-Week Results from FOREMOST, a Placebo-Controlled Study Involving Oligoarticular Psoriatic Arthritis Treated with Apremilast
Abstract Number: 0910

17β-estradiol and B-cell Intrinsic Type I Interferon Amplify Toll-like Receptor 7 Signaling Loop in B Cells of Female Lupus Prone BXD2 Mice
Abstract Number: 2394

18f-FDG-PET/CT for Giant Cell Arteritis Detection of Large Vessel Vasculitis: What Should We Take into Consideration? Analytical Study of the Arteser Registry
Abstract Number: 2019

2023 EULAR Recommendations for the Management of Fatigue in People with Inflammatory Rheumatic and Musculoskeletal Diseases
Abstract Number: 2167

24-week, Post-Marketing Surveillance Analysis of Upadacitinib in Japanese Patients with Rheumatoid Arthritis (Encore1)
Abstract Number: 1894

3-Dimensional Regional Variation in Inter-rater Reliability of Bone Marrow Lesion Scoring in the Knee
Abstract Number: L07

3-year Results of Tapering TNFi to Withdrawal Compared to Stable TNFi Among Rheumatoid Arthritis Patients in Sustained Remission: A Multicenter Randomized Trial
Abstract Number: 1723

3,3-dimethyl-1-butanol and Its Metabolite 3,3-dimethylbutyrate Ameliorate Arthritis Severity in CIA Independent of Choline TMA Lyase Activity
Abstract Number: 2185

35 Years Follow-up of Primary Sjögren’s Disease: A Single Center Study
Abstract Number: 2598

6 Months-follow up Data of Systemic Sclerosis Patients Treated with CD 19 Targeting CAR-T Cells

1
2
3
…
177
Next Page »

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.